drugset / Trial / NCT05005819
Evaluation of [18F]APN-1607 as a PET Biomarker
NaSingle-groupOpen-labelOther
Summary
The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
Timeline
- Start
- 2021-05-25
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APN-1607 | Diagnostic / imaging agent | — | Intravenous |